Terms: = Skin cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802
580 results:
1. Synthesis, bioactivity assessment, molecular docking and ADMET studies of new chromone congeners exhibiting potent anticancer activity.
Abo-Salem HM; El Souda SSM; Shafey HI; Zoheir KMA; Ahmed KM; Mahmoud K; Mahrous KF; Fawzy NM
Sci Rep; 2024 Apr; 14(1):9636. PubMed ID: 38671055
[TBL] [Abstract] [Full Text] [Related]
2. Overcoming BRAF and cdk4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
3. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
4. Trauma plays an important role in acral melanoma: A retrospective study of 303 patients.
Huang R; Zhao M; Zhang G; Yang Y; Wang J; Zheng K; Li L; Su X; Zhao L; Wu Y; Zou Z
Cancer Med; 2024 Apr; 13(7):e7137. PubMed ID: 38545846
[TBL] [Abstract] [Full Text] [Related]
5. Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.
Starace M; Rapparini L; Cedirian S; Evangelista V; Pampaloni F; Bruni F; Misciali C; Rubino D; Zamagni C; Pileri A; Piraccini BM
Support Care Cancer; 2024 Feb; 32(3):200. PubMed ID: 38421520
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ; Glassee N; Kicinski M; Blank CU; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Boers-Sonderen M; Giacomo AMD; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; van Akkooi ACJ; Gandini S; Buhrer E; Suciu S; Robert C; Eggermont AMM; Mandala M; Lorigan P; Valpione S
Eur J Cancer; 2024 Apr; 201():113585. PubMed ID: 38402687
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of Autophagy Aggravates
Tsai CH; Huang HC; Lin KJ; Liu JM; Chen GL; Yeh YH; Lu TL; Lin HW; Lu MT; Chu PC
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279345
[TBL] [Abstract] [Full Text] [Related]
8. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors.
Bang AS; Fay CJ; LeBoeuf NR; Etaee F; Leventhal JS; Sibaud V; Arbesman J; Wang JY; Kwong BY
Breast Cancer Res Treat; 2024 Apr; 204(3):643-647. PubMed ID: 38224427
[TBL] [Abstract] [Full Text] [Related]
9. Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of cdk4/6 inhibitor palbociclib to melanoma.
Attia MF; Ogunnaike EA; Pitz M; Elbaz NM; Panda DK; Alexander-Bryant A; Saha S; Whitehead DC; Kabanov A
Biomater Sci; 2024 Jan; 12(3):725-737. PubMed ID: 38099834
[TBL] [Abstract] [Full Text] [Related]
10. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired cdk4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
[TBL] [Abstract] [Full Text] [Related]
12. PRMT5 and cdk4/6 inhibition result in distinctive patterns of alternative splicing in melanoma.
Chan LH; Wang P; Abuhammad S; Lim LRJ; Cursons J; Sheppard KE; Goode DL
PLoS One; 2023; 18(11):e0292278. PubMed ID: 37917641
[TBL] [Abstract] [Full Text] [Related]
13. Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract] [Full Text] [Related]
14. Comparing the efficacy of plasma exeresis and cryotherapy for the treatment of seborrheic keratosis: A randomized controlled trial.
Noorbakhsh M; Kalantari Y; Ghasemi E; Shokri B; Mahmoudi H; Daneshpazhooh M; Etesami I; Khani M
Skin Res Technol; 2023 Aug; 29(8):e13429. PubMed ID: 37632194
[TBL] [Abstract] [Full Text] [Related]
15. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract] [Full Text] [Related]
16. Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI.
Arnfield EG; Tam L; Pattison DA; Younger J; Chikatamarla VA; Wyld D; Burge M; McCormack L; Ladwa R; Ramsay S
J Nucl Cardiol; 2023 Dec; 30(6):2676-2691. PubMed ID: 37587328
[TBL] [Abstract] [Full Text] [Related]
17. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.
Sibaud V; Sollena P
Ann Dermatol Venereol; 2023 Sep; 150(3):208-212. PubMed ID: 37586898
[TBL] [Abstract] [Full Text] [Related]
18. Successful continuance of cdk4/6 inhibitor treatment with palbociclib after abemaciclib-induced hepatotoxicity in breast cancer: a case report.
Ozawa Y; Fujimiya T; Shimada A; Okazawa A; Kusano J; Yamamoto R; Hyasashi S
Anticancer Drugs; 2024 Jan; 35(1):89-92. PubMed ID: 37578747
[TBL] [Abstract] [Full Text] [Related]
19. Artichoke as a melanoma growth inhibitor.
Mathew AM; Deng Z; Nelson CJ; Mayberry TG; Bai Q; Lequio M; Fajardo E; Xiao H; Wakefield MR; Fang Y
Med Oncol; 2023 Aug; 40(9):262. PubMed ID: 37544953
[TBL] [Abstract] [Full Text] [Related]
20. Preferential killing of melanoma cells by a p16-related peptide.
Soo JK; Castle JT; Bennett DC
Biol Open; 2023 Aug; 12(8):. PubMed ID: 37522264
[TBL] [Abstract] [Full Text] [Related]
[Next]
